Last update:

Clinical pharmacology news

New start-up aims to cut cost of producing proteins for cancer care and diagnostics

A new University of Kent start-up has been launched to commercialize biotechnology that could make it cheaper and easier to produce proteins used in cancer treatments, vaccines and diagnostic tests. Sirius Proteins was registered ...

Since the 21st Century Cures Act passed, FDA approvals have relied on fewer studies

Since the passage of the 21st Century Cures Act in 2016, Food and Drug Administration (FDA) approvals for new medical products have relied on fewer studies, according to a study published Aug. 26, 2026, in the PLOS ONE by ...

New mRNA immunotherapy eliminates pancreatic tumors in mice

Inspired by the work of the RNA Therapeutics Institute at UMass Chan Medical School and the development of the COVID vaccine, Marcus Ruscetti, Ph.D., and Chaitanya Naimesh Parikh, Ph.D. '26, have developed an immunotherapy ...

Study suggests new antibody therapy for tick-borne disease

Crimean-Congo hemorrhagic fever virus (CCHFV) is a dangerous virus spread by ticks. It transmits Crimean-Congo hemorrhagic fever (CCHF), a serious disease that has been spreading into new regions worldwide. Capable of killing ...

Q&A: Psychedelics, cannabis, GLP-1s and drug policy changes

From headlines and social media, psychedelic therapies, cannabis use and GLP-1 medications have seemingly become commonplace overnight, but the science underlying these treatments and the pathway to drug approval are often ...

Researchers study barriers to GLP-1 insurance coverage

Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage. University of Mississippi researchers are examining why and where that leaves patients.

Rise of GLP-1s raises long-term affordability questions

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022. ...

Drug hope for people with common heart thickening disease

A new drug offers hope for people with hypertrophic cardiomyopathy, the world's most common inherited heart disease. The TEMPEST trial, led by University of Manchester researchers, tested the drug—called trientine—in 154 ...

New malaria drug candidate shows promise in Phase I trial

The early-stage trial of a potential novel nonartemisinin malaria drug found it rapidly killed malaria parasites and was generally well tolerated in infected volunteers, showing it is a promising candidate for uncomplicated ...